Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 October 2006, Vol. 108, No. 7, pp. 2159-2164.
Prepublished online as a Blood First Edition Paper on June 8, 2006; DOI 10.1182/blood-2006-03-013086.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-03-013086v1
108/7/2159    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Offidani, M.
Right arrow Articles by Leoni, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Offidani, M.
Right arrow Articles by Leoni, P.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted March 28, 2006
Accepted May 17, 2006

Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for newly diagnosed multiple myeloma patients over 65 years

Massimo Offidani*, Laura Corvatta, Maria-Novella Piersantelli, Giuseppe Visani, Francesco Alesiani, Marino Brunori, Piero Galieni, Massimo Catarini, Maurizio Burattini, Riccardo Centurioni, Mario Ferranti, Serena Rupoli, Anna Rita Scortechini, Luciano Giuliodori, Marco Candela, Debora Capelli, Mauro Montanari, Attilio Olivieri, Antonella Poloni, Claudia Polloni, Monica Marconi, and Pietro Leoni

Clinica di Ematologia
Divisione Medicina Fabriano
Clinica di Ematologia Polo Ospedaliero Universitario Ospedali Riuniti Universita Ancona
Divisione Ematologia Pesaro
Unita di Oncoematologia S, Severino Marche
Divisione Medicina Fano
Divisione di Ematologia Ascoli Piceno
Divisione Medicina Macerata
Divisione Medicina Jesi
Divisione Medicina Civitanova Marche
Divisione Medicina Tolentino
Servizio di Oncologia Fabriano

* Corresponding author; email: m.offidani{at}ao-umbertoprimo.marche.it.

We present the results of a phase II study using thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 newly diagnosed multiple myeloma patients over 65 years. Thalidomide was administered orally 100 mg at bedtime continuously, dexamethasone orally 40 mg days 1-4 and 9-12 and pegylated liposomal doxorubicin intravenously 40 mg/m2 on day 1 over the 28-days cycle. Response was assessed according to the EBMT criteria. Seventeen (34%) patients achieved CR, 7 (14%) nCR, 5 (10%) VGPR, 15 (30%) PR and 5 (10%) MR resulting in an ORR of 98%. Only one patient (2%) presented progressive disease. Time to progression (TTP), event-free survival (EFS) and overall survival (OS) projected at 3 years were 60%, 57% and 74% respectively, and these parameters were significantly higher in those patients achieving a response ≥VGPR versus those who did not. Grade 3-4 nonhematologic adverse events were constipation (10%), fatigue (6%), tremors (4%), mucositis (4%) and palmar-plantar erythro-dysesthesia (2%). Grade 3-4 neutropenia occurred in 12% of patients. Grade 3-4 infections and thrombo-embolic accidents were observed in 22% and 14% of patients, respectively. In the treatment of elderly patients with newly diagnosed multiple myeloma, ThaDD is a very effective regimen with manageable toxicity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Complete response in myeloma: a Trojan horse?
Bart Barlogie and Guido Tricot
Blood 2006 108: 2134. [Full Text] [PDF]



This article has been cited by other articles:


Home page
JCOHome page
A. J. Jakubowiak, T. Kendall, A. Al-Zoubi, Y. Khaled, S. Mineishi, A. Ahmed, E. Campagnaro, C. Brozo, T. Braun, M. Talpaz, et al.
Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma
J. Clin. Oncol., October 20, 2009; 27(30): 5015 - 5022.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Rana and M. N. Levine
Prevention of Thrombosis in Ambulatory Patients With Cancer
J. Clin. Oncol., October 10, 2009; 27(29): 4885 - 4888.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al.
Thalidomide for treatment of multiple myeloma: 10 years later
Blood, April 15, 2008; 111(8): 3968 - 3977.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
C. W. Francis, A. K. Kakkar, M. N. Levine, and G. H. Lyman
Prevention of Venous Thromboembolism in Patients with Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 250 - 256.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
K Zervas, D Mihou, E Katodritou, A Pouli, C. Mitsouli, A Anagnostopoulos, S Delibasi, M. Kyrtsonis, N Anagnostopoulos, E Terpos, et al.
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
Ann. Onc., August 1, 2007; 18(8): 1369 - 1375.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist, June 1, 2007; 12(6): 664 - 689.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
S. Pulini, S. Rupoli, G. Goteri, N. Pimpinelli, R. Alterini, A. Tassetti, A. R. Scortechini, M. Offidani, S. Mulattieri, A. Stronati, et al.
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas
Haematologica, May 1, 2007; 92(5): 686 - 689.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc., March 1, 2007; 82(3): 323 - 341.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology, January 1, 2006; 2006(1): 338 - 347.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020